Lupin gets USFDA approval for suspension to treat allergic conjunctivitis
时间:2024-06-17 01:36:57 阅读(143)
Lupin gets USFDA approval for suspension to treat allergic conjunctivitis
Global pharma major Lupin Limited on Wednesday announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Loteprednol Etabonate Ophthalmic Suspension, 0.2 percent.
The approval has been granted to market a generic equivalent to the reference listed drug (RLD) Alrex Ophthalmic Suspension, 0.2%, of Bausch & Lomb Inc. The product will be manufactured at Lupin’s Pithampur facility in India.
Loteprednol Etabonate Ophthalmic Suspension, 0.2% (RLD Alrex), had estimated annual sales of USD 29.1 million in the U.S. (IQVIA MAT October 2023).
分享到:
温馨提示:以上内容和图片整理于网络,仅供参考,希望对您有帮助!如有侵权行为请联系删除!
猜你喜欢
- US stocks- Futures subdued ahead of Fed rate decision
- ITC, GCPL, Bajaj Auto among 40 NSE stocks to hit 52-week highs; 11, including Nykaa, touch 52-week lows
- US Stocks- S&P 500 to open lower as UK’s Truss resigns as PM
- ONGC Videsh to get oil from Venezuela in lieu of $600 million dividend
- US Stocks- Nasdaq falls as megacaps drop ahead of earnings, Fed meet in focus
- Investors betting big on passive funds; AUM up 8
- Paytm, Nestle, Tata Motors, Titan, NTPC, IDFC among 129 NSE stocks to hit 52-week highs; 13 touch 52-week lows
- IREDA public issue to open on November 21; sets price band at Rs 30-32 share
- US Stocks- Futures decline as China COVID cases rise; Disney jumps